Introduction
Vagus nerve stimulation (VNS) has shown promising results in various cohorts of non-surgical refractory epilepsy in adults and children. We enrolled the first 28 children and adolescents treated with VNS in our institution in a protocol designed to assess the efficacy and optimal use of VNS in children with refractory epilepsy classified by epileptic syndromes. As most children were experiencing multiple seizures per day, we developed a 6-week rapid ramping protocol. Their medication was not modified for the first 6 months of therapy. We report the outcome at the 6 and 24 months follow-up visits.
Methods
All patients treated with VNS at our institution between January 2000 and December 2004 were included in this study. All patients and their caregiver were required to keep a detailed seizure diary 2 months prior to implantation and for the ensuing follow-up period. Baseline investigations consisted of video-EEG monitoring, cerebral magnetic resonance imaging and functional imaging studies to exclude the presence of a surgically removable epileptic focus. Neuropsychological evaluation was obtained prior to VNS in all patients, and 6 months after initiation of VNS in the first 16 patients. Medications were kept unchanged during the first 6 months, after which they could be adjusted as necessary by the treating neurologist.
Visits were performed weekly for the first 6 weeks to increase stimulus intensity from 0.25 mA set at the time of surgery to 1.5 mA, then monthly up to 6 months and as needed over the next 18 months. At each visit, a new seizure diary was given to the parents in order to document the evolution of each type of seizures. EEGs were performed at 6 and 24 months follow-up and when increased seizure frequency or apparition of new seizure types were noted. EEG recordings were obtained on Stellate EEG machines and traces were analyzed using Stellate Harmonie Software (Mtl, Canada). Side effects were recorded throughout the follow-up period.
Results
Baseline data and epilepsy classification (Table 1) Patients were aged between 2 months and 7 years old when their epilepsy was diagnosed. We treated 13 males and 15 females. Specific epileptic syndromes were diagnosed when possible. There were three generalized idiopathic epilepsies with absence seizures, five Lennox-Gastaut syndrome, two severe infantile myoclonic epilepsy of Dravet, one myoclonic epilepsy of Doose, five cryptogenic generalized epilepsies, seven cryptogenic bilateral partial epilepsies, and five partial symptomatic epilepsies (two bi-frontal and three bilateral independent). 1 No child had an underlying metabolic disorder. Before initiation of VNS, patients had received 3-13 medications at therapeutic levels (mean of 9 medications per child). The ketogenic diet had failed in 18 patients. The other patients were deemed unsuitable for ketogenic diet therapy due to medical or nutritional problems. In addition, three patients had failed prior surgical treatment: two callosotomies, and one frontal lobectomy.
Pre-implantation cognitive functional level
All patients had a neuropsychological evaluation prior to VNS initiation and all, except those with idiopathic generalized absence epilepsy, were cognitively impaired. They were classified as suffering from severe mental retardation (21%: 6/28), moderate mental retardation (39%: 11/28), or mild mental retardation (29%: 8/28) as assessed with the Bayley scales of infant development or the Wechsler's pre-school and primary scale of intelligence (WIPSI III) with mild mental retardation defined as IQ 55-70, moderate IQ 40-55 and severe IQ < 40.
Effects of VNS on seizure type, epileptic syndrome, and EEG changes (Table 1 and Supplemental Table 1) Patients were between 3 (1/2) and 21 years old when VNS therapy was initiated, the older patient being a severely disabled child with Lennox-Gastaut syndrome. The mean delay between diagnosis of epilepsy and VNS therapy was 7 years (range: 2-17 years). All but four patients completed the 24 months follow-up period.
At 6 months, seizures were reduced by >50% in 21/28 children (75%). At 24 months of follow-up, this favorable outcome persisted in 68% of our patients (19/28) (Fig. 1) . Six responders showed an additional improvement after 6 months. These changes in seizure control were not related to specific changes in seizure medication.
In contrast, four patients who had an initial response at 6 months lost seizure control at 24 months.
At 2 years, the mean seizure reduction rate was 53% per patient. In our population, seizures that were the most responsive to VNS therapy included atonic (86% > 50% reduction), tonic (100% > 50% reduction) and myoclonic seizures (75% > 50% reduction) (Fig. 2) . Those seizures are frequently seen in patients with refractory generalized epileptic syndromes. For instance, in children with Lenox-Gastaut syndrome, 3/5 patients showed 50% seizure reduction and a fourth had his generalized tonico-clonic seizures and tonic seizures controlled but with the persistence of atypical absence seizures. Our patient with Doose syndrome became seizure-free at 2 years. The other generalized epilepsies with myoclonic seizures had a good response to VNS with 60% (3/5) showing 75% seizure reduction, while two showed no or mild responses. Of the two patients with Dravet syndrome, one had 90% seizure reduction while the other had no response. But partial epilepsies also responded very well to treatment with 9 patients out of 12 showing significant improvement: 1 with 50% reduction, 1 with 75% reduction, 6 with 90% reduction and 1 becoming seizure-free.
Three patients had previous epilepsy surgery and their results were comparable to that of other children.
The analysis of post-VNS EEG in our patients did not show consistent modifications of ictal or interictal EEG patterns at 6 or 24 months.
Medication modifications following VNS
28% (8/28) patients remained on the same medications throughout follow-up. We were able to decrease the therapeutic regimen in only 14% of children (4/28). One patient was free of medication at follow-up. In 57% (16/28), one anticonvulsant was tapered but replaced by a new medication. 
Effects of VNS on cognitive functions, behavior and quality of life
No change in level of cognitive functioning was observed between baseline and 6-month evaluations in 16 children tested at both time-points. However, in 69% (11/16) of our patients the neuropsychologist reported improvement in alertness, playfulness and global interaction, and 93% (26/28) the caregivers reported improved nigh time sleep.
Side-effects and adverse outcomes 68% (19/28) of our patients experienced one or more side effects. Most children complained of minor adverse events such as throat pain, voice change, chest discomfort, local thoracic pain at site of VNS battery, dyspnea, coughing or mild dysphagia which were either transitory or tolerable.
Two patients (#11, 17) had severe discomfort at the site of VNS battery and necessitated surgical repositioning. Deep infection required VNS removal and antibiotic treatments in two patients (#3, 26). For these four patients, VNS was reinstituted within few weeks with similar benefits as recorded prior to removal. Two patients were considered as drop-outs and recorded as failure of VNS therapy (no significant impact on seizure frequency): one child complained of severe dysphagia requiring removal of the device (#8), and a severely disabled child (#6) died from upper airway obstruction when he was left unattended eating solid foods two months following initiation of VNS.
Discussion
Effect of VNS on seizure frequency VNS studies in adults have shown a mean seizure reduction of 49-64% at 2 years, with 43-75% of patients showing 50% reduction in seizure frequency. Results in pediatric studies have been more variable. Mean seizure reduction varies between 42 and 58%, but follow-up has often been limited to 6-18 months. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Percentages of patients showing >50% reduction in seizure frequency vary between 37 and 75%, with 5-18% of patients becoming seizure-free. Our results are in the upper range of pediatric studies. Response rate was higher at 6 months with our protocol.
The results in our small cohort confirm previously reported efficacy in Lennox-Gastaut syndrome. 2, 7, 8, 12, 15 In addition, we demonstrate similar efficacy in other cryptogenic generalized and partial epilepsies. Regarding seizure type, generalized tonic clonic seizures appear to be the most refractory to VNS therapy. However, we demonstrate particular efficacy of VNS against seizures potentially associated with falls and injuries.
Side effects
Side effects occurred in 68% of our patients, and most were mild or transient. This is elevated compared to other pediatric studies. In 16 Mild adverse events such as throat discomfort and hoarseness are frequently reported in the immediate post-implantation period (30 and 60% of patients, respectively) but tend to diminish with time as in our cohort, reaching 4.7 and 18.7% at 5 years. 17 By comparison, six of our patients experienced severe side effects including two infections requiring removal of the implant and antibiotic treatment, with subsequent reimplantation of VNS, two severe discomforts at the site of the battery requiring surgical repositioning, and two cases of severe dysphagia. In the cases where VNS was reimplanted, therapeutic effects were comparable following reimplantation as prior to removal. We have not experienced a significant complication during surgical procedures and these side effects were thus considered severe but amendable to therapy. Infections at the site of implants have been reported in the literature as affecting 3-11% of patients in other series. It has been suggested that most of these infections may be treated by antibiotics alone and do not necessitate removal of the device. 18 Cases of severe dysphagia with VNS therapy have been previously reported, and this may in some cases lead to aspiration pneumonia as reported by Lundgren et al. 19 In our cohort, the unfortunate death of patient #6 could not be clearly attributed to VNS as the child was left unsupervised with solid food.
Behavior, cognition and quality of life
We have observed improved behavior and attention despite absence of cognitive changes in our cohort. This may be partly attributable to improved sleep as reported by caregivers for 26 of our patients. Although sleep was not studied formally in our cohort, improved daytime sleepiness has been reported by Malow et al. in 15 subjects treated with VNS and evaluated with multiple sleep latency tests. 20 The review of 687 pediatric patients from the Cyberonics Patient Outcome registry also showed that alertness was improved in more than 70% of children at 12 months. 21 In a retrospective review of autistic children treated with VNS, Park described improvement in alertness in 76% of patients. 22 In addition, quality of life seems to be improved in the vast majority of patients treated with VNS, irrespective of seizure control, and we suspect this to be partly attributable to improved sleep. Despite improvement on seizure frequency, VNS did not modify cognitive functions in our patients. This is in line with previous reports. In a cohort of 160 patients, Dodrill and Morris used various neuropsychological tests and detected no significant difference between baseline and follow-up cognitive functions. 23 Similarly, a prospective study of 36 adults followed over 6 months with formal neuropsychological testing did not reveal any significant change over time in cognitive performance. 24 
Conclusion
Our results show that VNS parameters can be increased weekly leading to an early clinical response, which is sustained at 2 years. This more aggressive ramping pattern is associated with significant improvement at 6 months and even earlier, but should be limited to children with multiple daily seizures because it also leads to a higher rate of adverse events. Extra caution must be exercised in cognitively impaired children as rapidly increasing parameters might aggravate pre-existing dysphagia.
In addition to seizure improvement, other benefits of VNS in childhood refractory epilepsy must also be stressed, including significant improvements in alertness, nigh time sleep and behavior.
